ViroPharma down on pleconaril data

VPHM was down $48.50 (68 percent) to $23.25 on Tuesday after missing the primary end points in three Phase III trials of pleconaril to treat two

Read the full 264 word article

How to gain access

Continue reading with a
two-week free trial.